Comparison of the efficacy of oxtyocin agonist to oxytocin in the prevention of postpartum hemorrhage (PPH) in women undergoing vaginal delivery
Dr Farouk
720 participants
Dec 13, 2006
Interventional
Conditions
Summary
This study is intended to compare the efficacy and safety of an oxytocin analogue and oxytocin in the prevention of postpartum hemorrhage (massive bleeding after birth) in women undergoing vaginal delivery. Oxytocin and its analogue are drugs used to contract the uterus to prevent postpartum hemorrhage. We would like to compare the effect of the drugs to lower the need for additional intervention (additional massage or other uterotonic needed) in the prevention of PPH postpartum hemorrhage.
Eligibility
Inclusion Criteria1
- Normal and healthy women who will undergo vaginal delivery, Parity I-IV, Singleton pregnancy with cephalic presentation
Exclusion Criteria1
- Primigravida or Para V and above, History of PPH and/or uterine atony in the previous delivery, History of cardiac arrhythmia or any other clinically significant heart diseases, History of hypertension requiring treatment within the last 2 years, History of anaemia (Hb <10 g/dL), Known or suspected coagulopathy (hereditary or acquired) (eg. von Willebrand’s disease, etc), History or evidence of chronic liver, renal or endocrine disease, History of hypersensitivity to oxytocin or carbetocin, Placenta previa or abruptio placentae, Any sign of pre-existing uterine pathology or anomaly, Rupture of membrane
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For the management of 3rd stage of labour at vaginal delivery, 100 microgram Intramuscular (IM) slow bolus injection of oxytocin agonist after infant is delivered
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000396325